JAK2 and acute lymphoblastic leukemia: Incorporation of imatinib into treatment approaches for Ph+ ALL has also drastically improved EFS rates, from 27% to 72% (Senkevitch and Durum, 2017), suggesting that similar approaches may also be successful for the treatment of JAK2-altered ALL.